Eli Lilly CEO on New Drug Manufacturing, GLP-1 Market Share, and US Production

US Drug Manufacturing Expansion

• 🇺🇸 Eli Lilly is investing $4.5 billion in a new "Medicine Foundry" to scale up drug production and develop manufacturing technology in the US.
• 🤝 The company met with President Trump to discuss expanding US manufacturing, supporting his executive order to streamline regulatory processes.
• 🏭 This new site is part of a larger $50 billion expansion plan for Eli Lilly, aiming to bring medicine production back to the US and reduce reliance on overseas markets like China.

Job Creation and Economic Impact

• 💼 The $50 billion expansion is expected to create over 10,000 new manufacturing and science jobs, plus more than 25,000 construction jobs.
• 🏗️ Mega-sites are being built with the help of skilled trades from around the country, providing a significant boost to the construction industry.
• 🌍 Bringing production back to the US is critical for creating jobs, ensuring proximity to the market, and enhancing national security.

GLP-1 Market Leadership

• 📈 Eli Lilly now holds a 53% share of the GLP-1 market, surpassing Novo Nordisk and leading in new patient starts for obesity treatment.
• 🎯 These GLP-1 drugs, like Zepbound and Mjaro, are considered "game-changing" for treating obesity, which affects 40% of adults and drives chronic diseases.
• 💊 The company is also developing an oral GLP-1 pill, expected next year, and is working to improve insurance coverage and lower costs for these medications.

Drug Safety and Efficacy

• ❤️ GLP-1 medications have shown profound impacts on long-term health, including reductions in sleep apnea, heart disease, and diabetes prevention.
• ⚠️ Common side effects are typically gastrointestinal upset, and specific patient groups with hereditary or prior health conditions should consult a physician.
• 🩺 Eli Lilly has extensive experience with GLP-1s, having launched the first one 20 years ago, and expresses confidence in the broad safety profile of these medicines when used under physician guidance.